September 2007
To view the abstract, please click here
AEROECLIPSE* II Breath Actuated Nebulizer (BAN) Minimizes Fugitive
Emissions
The AEROECLIPSE* II BAN generates aerosol only in response to
the patient's inspiratory flow. Fugitive emissions are reduced by minimizing
the amount of medication released into the hospital environment. All other
air-entrained nebulizers continuously produce aerosol regardless of whether
the patient is inhaling, exhaling or resting – resulting in unnecessary
exposure for healthcare providers.
Fugitive emissions refer to the amount of drug that is released into the
surrounding environment during a patient treatment. The AEROECLIPSE*
II BAN is superior at significantly reducing fugitive emissions because the
patient’s inspiratory breath is controlling the aerosol therapy. Even
breath-enhanced nebulizers have significant emissions, because aerosol is
still being created during the exhalation phase of each breathing cycle.
In a study presented at the 2007 European Respiratory Society Annual
Conference in Stockholm, Sweden, the fugitive emissions from the
AEROECLIPSE* II BAN represented about 4% of the mass of medication
placed in the reservoir, significantly less than the continuously operating
air entrainment nebulizer which resulted in environmental losses of 21%.
By reducing the amount of drug lost to the environment the
AEROECLIPSE* II BAN offers the following benefits:
-
Virtually no aerosol is produced during expiration
-
Clinical dose assurance
-
Environmental protection for caregivers and healthcare providers
-
Less wasted medication
When you use the
AEROECLIPSE* II BAN the prescribed medication is delivered to
where you need it most… deep into your lungs.
For the full abstract,
please click here.
® trade-marks and registered trade marks of Trudell Medical
International © Trudell Medical International 2007. All rights
reserved.
Privacy Policy